

Case Review of Melioidosis in Tertiary Care Hospital, Northern Sri Lanka.

Selladurai Pirasath¹, Jeebananthi Pradeepan², Thirunavukarasu Kumanan²

¹ Registrar, ² Consultant Physician and Senior Lecturer in Medicine, Professorial **Medical Unit**, Teaching Hospital, Jaffna, Sri Lanka,

Correspondence: email:selladuraipirasath81@gmail.com

Key words: melioidosis, *Burkholderia pseudomallei*, septic arthritis, pneumonia, abscess, diabetes, northern, Sri Lanka.

Abstract

Melioidosis is sporadically reported from various parts of Sri Lanka. It is major recent endemic in Northern **Sri Lanka**. It is caused by *Burkholderia pseudomallei*, a Gram-negative, oxidase positive bacillus. The first case of melioidosis was reported in a European tea broker in 1927 in Sri Lanka. We present a case series of seven patients of culture or serologically proven melioidosis from Northern Sri Lanka, highlighting the different clinical manifestations of the disease. Melioidosis had a varied presentation involving multiple abscesses in the skin, liver, spleen, mediastinum and septic arthritis. It presented as either an acute fulminant septicemia with a high mortality to a chronic localized infection. Most cases had predisposing risk factors such as diabetes and occupational risk.

Introduction

Melioidosis is acute or chronic pyogenic infection, caused by bacterium *Burkholderia pseudomallei* from soil (1). It occurs following inoculation of skin and causes illness in humans and animals. It is **endemic** in tropical and subtropical areas of South East Asia

(2). The first case of melioidosis was reported in a European tea broker in Sri Lanka in 1927 (3). Recently, several cases of melioidosis have been reported in Sri Lanka, probably due to an increase in international travel to endemic areas (4). Diabetes mellitus, chronic alcoholism, chronic obstructive airway disease, or chronic kidney disease, cancer and steroid therapy are common risk factors (5). Here, we describe seven cases of melioidosis patients in Northern Sri Lanka and highlight the spectrum of clinical manifestation. Informed consent was obtained from all patients in Jaffna district.

Case Series

Case 1

A 58 years old diabetic woman presented fever with constitutional symptoms, severe bilateral knee joint pain and swelling. On examination, she had moderate soft tender hepatomegaly and bilateral fine basal crepitations. Bilateral knee joint with active inflammation was noted in right side more than left side. The clinical investigations performed are shown in Table 1. The joint fluid analysis revealed polymorpholeucocytosis predominant lymphocytosis with elevated protein level and *Burkholderia pseudomallei* was isolated from joint fluid culture. Melioidosis antibody titre was 5120 and was managed with intravenous ceftazidime and cotrimaxazole for two weeks. Her condition was deteriorated and she died due to septic shock with multi-organ dysfunction during 3rd week in course of therapy.

Case 2

A 49 year old diabetic woman presented with fever and productive cough with whitish coloured sputum for one week duration. She was involved actively in cultivation. On examination, she had right side middle and lower zone crepitations and moderate soft

tender hepatosplenomegaly. The clinical investigations performed are shown in Table 1. Her ultrasound abdomen showed focal liver lesion suggestive of abscess/metastasis. The contrast enhanced computerized tomography of chest and abdomen revealed large lesion with peripheral echogenicity with right hilar lymphadenopathy and two focal lesions measuring 2.2 & 1.5cm and 2.4 & 1.5cm in segment 5 and 6 of liver suggestive of lung and hepatic abscess. Even, the repeated blood cultures were negative; her serum melioidosis antibody titre was 10,240. She was treated with intravenous meropenem and oral doxycycline for six weeks and was discharged with course of oral antibiotic. At 6 months of follow-up he had no signs of recurrence.

Case 3

A 27-year-old female presented with fever with constitutional symptoms for three weeks duration. She was febrile, pale and had tachycardia and tachypnoea. Her systemic examination is unremarkable. The contrast enhanced computerized tomography of abdomen revealed septated abscess measuring size of 3.6 cm & 4.8 cm + size in spleen. Her serum melioidosis antibody titre was 10,240. She was treated with intravenous meropenem and oral doxycycline. At 6 months of follow-up, the hip pain had subsided, she had gained weight and the splenomegaly had completely regressed.

Case 4

63 years old diabetic man presented with fever with constitutional symptoms, abdominal pain, watery diarrhea and productive cough for two weeks duration. On examination, he was pale, with tachycardia. He had bilateral lower zone crepitations and moderate soft tender hepatomegaly. His chest X ray showed bilateral patch shadow. His ultrasound of abdomen showed septated abscess in spleen. *Burkholderia pseudomallei* was isolated

from blood culture. Even on treatment with meropenem and clathromycin, he developed septic shock, acute respiratory distress syndrome. However, the patient developed refractory sepsis, required a ventilator and subsequently succumbed to sepsis with multiorgan dysfunction.

Case 5

57 years old poorly controlled diabetic man presented with fever with constitutional symptoms, multiple skin abscess of left lower limb and back of chest and active inflammation of left side knee joint. On examination, he was pale, with tachycardia. He had bilateral lower zone crepitations and septic arthritis of left side knee joint. The joint fluid analysis revealed polymorpholeucocytosis predominant neutrophils with elevated protein level and *Burkholderia pseudomallei* was isolated from blood culture. His chest X ray showed bilateral patch shadow. His ultrasound of lower limbs showed deep seated abscess in left side thigh and calf region. He underwent drainage of deep abscess and knee joint aspiration. He developed septic shock and acute respiratory distress syndrome and required a ventilator. Subsequently improved with meropenem and cotrimaxzole for six weeks and was discharged with course of oral antibiotics. At 6 months of follow-up, he had no signs of recurrence.

Case 6

A 34 year old female presented with fever with constitutional symptoms for three weeks duration. The contrast enhanced computerized tomography of abdomen revealed 21 cm size of spleen. The infectious, retroviral, septic and autoimmune screening was negative. Blood picture showed normocytic normochromic anemia and thrombocytopenia. Her serum melioidosis antibody titre was 640. She was treated with intravenous meropenem

and oral cotrimaxazole for 6weeks duration. At 6 months of follow-up, she had gained weight and the splenomegaly had completely regressed.

Case 7

14 years old healthy boy presented with fever with chills, rigors and productive cough for two weeks duration. On examination, he was with tachypnoea and tachycardia. He had lower zone coarse crepitations of right side lung. His chest X ray showed lung abscess with fluid level of right lung. His sputum culture, sputum FB were negative. His serum melioidosis antibody titre was 320. He was treated with intravenous meropenem and oral cotrimaxazole for 6weeks duration and lung abscess had been completely regressed.

Discussion

Burkholderia pseudomallei infection is an important emerging pathogen in Sri Lanka. It may be acute or chronic pyogenic infection and is capable of causing various clinical manifestations like pneumoniae, septicaemia, arthritis, abscess etc. and is associated with high morbidity and mortality (2). It is usually geographically restricted to tropical and subtropical areas of Australia and Southeast Asian countries (6). Isolated cases have also been reported from eastern and northeastern parts of Sri Lanka. The first case of melioidosis was reported in Jaffna in 2013 (7). Subsequently two cases were reported in 2016 (8).

The known endemic distribution of *B. pseudomallei* is expanding well beyond the traditional melioidosis-endemic regions of Southeast Asia and northern Australia, with recent case reports of melioidosis from the Americas, Madagascar, Mauritius, India and elsewhere in south Asia, China and Taiwan(2). Even though Sri Lanka has been considered non endemic for melioidosis, there is increasing evidence for its emergence in the recent past.

Diabetes mellitus, chronic alcoholism, chronic obstructive airway disease, or chronic kidney disease, cancer and steroid therapy are common risk factors (5). The diabetes found a correlation of 76% with Melioidosis (9). Diabetes mellitus was underlying risk factor among three cases.

The clinical presentation varies from a septicemia to chronic infection associated with high morbidity and mortality (2). It causes different clinical manifestations such as pneumonia, septicemia, arthritis and abscess. The lung involvement is the commonest clinical manifestation. Lung was involved among five cases in the form of either lung

abscess or pneumonia. Bone disease was reported in 16% of cases (10). Septic arthritis was the clinical manifestation in two cases. The cutaneous or deep seated or visceral abscess is also reported as common clinical manifestation (11). There were four cases of abscess reported in our cases.

The gold standard diagnostic investigation is isolation of *Burkholderia pseudo mallei* in culture from blood or serous fluids (6). However, prior antibiotics therapy leads to negative blood culture in our patient. The serological test is useful for diagnosis of melioidosis in culture negative cases (12). The serological test was positive among most of the cases and culture from blood or joint fluid was positive in certain cases in our study.

The current convention is to view the treatment of melioidosis as comprising two phases: The acute phase is aimed to stop patients from dying of overwhelming sepsis. The eradication phase is aimed to kill any residual bacteria and to minimize the risk of the infection relapsing. There have been several attempts to formulate clinical guidelines for melioidosis (13, 14). The key recommendations were use of ceftazidime or a carbapenem antibiotic for initial treatment of acute infection over 2-4 weeks and a combination of cotrimoxazole and doxycycline for eradication over a 12-20 week period (13,14). More recently, those recommendations were updated by an Australian group noted for clinical trials on melioidosis therapy (15). International consensus recommendations for the treatment and prophylaxis of melioidosis were developed by an expert group that met in Australia in 2010 (16)

Meropenem is the drug of choice in complicated melioidosis and ceftazidime is drug of choice in uncomplicated melioidosis (16). Co-trimoxazole, imipenem or coamoxiclav are alternatives for systemic melioidosis in acute phase (17). The oral cotrimoxazole or coamoxiclav is recommended therapy for eradication phase (16). Doxycycline is also used as alternative to prevent relapse (18) in follow up. Intravenous meropenem and oral co-trimoxazole or doxycycline were intensive therapy for six weeks and oral co-trimoxazole or doxycycline was maintenance therapy for most of our patients. Five patients improved with antibiotics therapy.

Late diagnosis has led to fatality in some studies, even proper therapy has been initiated (18). One case was probably missed due to lack of clinical awareness and correct microbiological diagnosis. A high index of suspicion is needed for diagnosis due to its varied clinical presentations. Nonspecific presentation and delayed diagnosis cause a great clinical challenge to clinicians and lead to the high mortality and morbidity of patients. At the same time, the case series highlight the need for improved microbiology services in patient care management. We were able to successfully treat the case by institution of correct antimicrobials based on microbiology feedback.

Conclusion

The proper clinical assessment and availability of microbiological cultures play key role for early detection of cases of melioidosis. Best clinical judgment and focused microbiological investigations are very important for early diagnosis. Poor awareness of melioidosis among health care personnel was probably contributed to the high case

fatality rate. Therefore, it is important to recognize patterns of melioidosis to prevent mortality and morbidity in Northern Sri Lanka.

Acknowledgements

We thank Consultant Physicians for their role of diagnosis and treatment of patients. In addition, we thank Consultant Microbiologist, Teaching Hospital, Jaffna and staff of Department of Microbiology, University of Colombo and for serological diagnosis and antimicrobials guidance of Melioidosis during the course of these studies.

Funding

Not applicable

Authors' contributions

SP was involved in collecting data and drafting the manuscript. JP was involved in collecting data and revising it critically. TK **was** involved in drafting the manuscript and revising it critically. All authors **were** involved in patient care and carried out the clinical assessment and have read and approved the final manuscript.

Ethics approval and consent to participate

The informed written consent was obtained from the participants for publication of the case reports to the journal.

Competing interests

The authors declare that they have no competing interests.

References

1.Cheng AC, Currie BI. Melioidosis: Epidemiology, Pathophysiology and Management.

Clin Microbiol Rev. 2005; **18**: 383-416.

<https://www.ncbi.nlm.nih.gov/pubmed/15831829>

2. Dance, D. A. Melioidosis as an emerging global problem. *Acta Trop* 200;**74**:115–119.
<https://www.ncbi.nlm.nih.gov/pubmed/10674638>
3. Denny CR. Melioidosis in a European. *Cey J Sci* 1927; **2**: 37-40.
<https://www.cabdirect.org/cabdirect/abstract/19272701945>
4. Corea E, Dharshan de Silva A, Thevanesam V Melioidosis in Sri Lanka. *Trop. Med. Infect. Dis.* 2018;**3**: 22
<https://www.mdpi.com/2414-6366/3/1/22>
5. Leelarasamee A. Epidemiology of melioidosis. *J. Infect. Dis. Antimicrob. Agents* 1986; **3**:84–93.
<https://pdfs.semanticscholar.org/0b1f/2ecd363d68b5256a1a2d20b14034375b7b07.pdf>
6. Corea E, Thevanesam V, Perera S, Jayasinghe I, Ekanayake A, Masakorala J, Inglis T. Melioidosis in Sri Lanka: an emerging infection. *Sri Lankan J Infect Dis* 2012;**1**: 2–8.
<https://sljid.sljol.info/articles/10.4038/sljid.v2i1.3801/>
7. Caldera, A.S.; Kumanan, T.; Corea, E. A rare cause of septic arthritis: Melioidosis. *Trop. Doct.* 2013; **43**:164–6.
<https://www.ncbi.nlm.nih.gov/pubmed/24067292>
8. Pirasath S, Selvaratnam G, Kumanan T, Pradeepan J, Mubarak FN. Melioidosis: Emerging infection in northern Sri Lanka. *Int. J. Med. Microbiol. Trop. Dis.* 2016; **2**:112–4.
<http://repo.jfn.ac.lk/med/bitstream/701/1467/1/Dr.Ku.pdf>
9. Vidyalakshmi K, Shrikala B, Bharathi B, Suchitra U. Melioidosis: An under-diagnosed entity in western coastal India: A clinico-microbiological analysis. *Ind J Med Microbiol.* 2007;**25**: 245–8.

<https://www.ncbi.nlm.nih.gov/pubmed/17901643>

10. Mukhopadhyay C, Chawla K, Krishna S, Nagalakshmi N, Rao SP, Bairy I. Emergence of *Burkholderia pseudomallei* and pandrug-resistant non-fermenters from southern Karnataka, India. *Trop Med Hygiene* 2008;**102**:S12–7.

<http://www.mdpi.com/2414-6366/3/2/51/s1>

11. Mathurageethan, M.; Kahathuduwa, C.N.; Badanasinghe, N.; Corea, E.; Fernando, R. Melioidosis associated with chronic osteomyelitis and visceral organ abscesses. *Sri Lanka J. Surg.* 2014; **32**:41–42.

<https://sljs.sljol.info/articles/10.4038/sljs.v32i2.7358/>

12. Alexander, A.D.; Huxsoll, D.L.; Warner, A.R.; Shepler, V.; Dorsey, A. Serological diagnosis of human melioidosis with indirect haemagglutination and complement fixation tests. *Appl. Microbiol.* 1970; **20**:825–33.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC377056/>

13. Wuthiekanun V., Peacock S.J. Management of melioidosis. *Exp. Rev. Anti-Infect. Ther.* 2006;**4**:445–455.

<https://www.ncbi.nlm.nih.gov/pubmed/16771621>

14. Inglis T.J., Rolim D.B., Rodriguez J.L. Clinical guideline for diagnosis and management of melioidosis. *Rev. Inst. Med. Trop. São Paulo.* 2006;**48**:1–4

<https://www.ncbi.nlm.nih.gov/pubmed/16547571>

15. Cheng A.C., Currie B.J. Melioidosis: epidemiology, pathophysiology, and management. *Clin. Microbiol. Rev.* 2005;**18**:383–416.

<https://www.ncbi.nlm.nih.gov/pubmed/15831829>

16. Lipsitz R., Garges S., Baccam P., Blaney D.D., Currie B.J., Dance D. Workshop on treatment of and postexposure prophylaxis for *Burkholderia pseudomallei* and *B. mallei* infection, 2010. *Emerg Infect Dis.* 2012;18

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557896/>

17. Sookpranee M, Boonma P, Susaengrat W, Bhuripanyo K, Punyagupta S. Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis. *Antimicrobial Agents Chemo.* 1992;**36**:158–62.

<https://www.ncbi.nlm.nih.gov/pubmed/1590682>

18. Cheng AC, Fisher DA, Anstey NM. Outcomes of Patients with Melioidosis Treated with Meropenem. *Antimicrob Agents Chemother.* 2004; **48 (5)**: 1763–65.

<https://www.ncbi.nlm.nih.gov/pubmed/15105132>

Table 1: The epidemiological, clinical, investigation and treatment profile of patients with melioidosis in a tertiary care centre, Northern Sri Lanka.

Characteristics	Case						
	1	2	3	4	5	6	7
Year	2015	2016	2016	2016	2016	2017	2017
Age (years)	58	49	28	63	57	34	14
Sex	Female	Female	Female	Male	Male	Female	Male
Occupation	Housewife	Housewife	Financial Assistant	Farmer	Farmer	Housewife	Student
Risk factors	-	DM	-	DM	DM	-	-
Clinical Presentation	Pneumonia	Lung abscess	Splenic abscess	Pneumonia	Pneumonia	Splenic abscess	Lung abscess
	Septic arthritis	Liver abscess		Splenic abscess	Septic arthritis		
					Cutaneous & Deep abscess		
Hb (10g/dL)	+	+	+	+	+	+	-
Leucocytosis	+	+	+	+	+	+	+
ESR	126	126	60	110	130	112	100
CRP	228	246	93	336	280	207	90
Chest X ray	Pneumonia	Pneumonia, Lung abscess	-	Pneumonia	Pneumonia	-	Lung abscess
USS Abdomen	Hepatomegaly	Hepatomegaly Liver abscess Splenomegaly	Splenic abscess	Splenic abscess	-	Splenomegaly	-
Blood Cultures	-	-	-	+	+	-	-
Melioidosis antibody	5120	10,240	10,240	N/A	N/A	640	320
Antibiotics sensitivity	CZM, MER	MER CTX	CZM MER	MER CTX	CZM MER	CZM MER	
	CTX	DOX	CTX DOX	IMI	CTX DOX	CTX DOX	
Outcome	Died	Survived	Survived	Died	Survived	Survived	Survived

Abbreviations: DM; diabetes mellitus, ESR:Erthrocyte sedimentation rate, CRP:C reactive protein, USS:Ultrasoundscan, CSZ:Ceftazidime, MER:Meropenem, CTX: Cotrimaxazole, DOX:Doxycyline.

: